KR102517273B1 - ENaC 억제제로서의 벤조디아졸륨 화합물 - Google Patents

ENaC 억제제로서의 벤조디아졸륨 화합물 Download PDF

Info

Publication number
KR102517273B1
KR102517273B1 KR1020197016141A KR20197016141A KR102517273B1 KR 102517273 B1 KR102517273 B1 KR 102517273B1 KR 1020197016141 A KR1020197016141 A KR 1020197016141A KR 20197016141 A KR20197016141 A KR 20197016141A KR 102517273 B1 KR102517273 B1 KR 102517273B1
Authority
KR
South Korea
Prior art keywords
amino
methyl
ium
pyrrolo
benzodiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016141A
Other languages
English (en)
Korean (ko)
Other versions
KR20190084076A (ko
Inventor
클라이브 매카시
조나단 데이비드 하그레이브
던컨 알렉산더 헤이
토마스 보르가드 쇼필드
나오미 웬트
Original Assignee
엔터프라이즈 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔터프라이즈 테라퓨틱스 리미티드 filed Critical 엔터프라이즈 테라퓨틱스 리미티드
Publication of KR20190084076A publication Critical patent/KR20190084076A/ko
Application granted granted Critical
Publication of KR102517273B1 publication Critical patent/KR102517273B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197016141A 2016-11-22 2017-11-22 ENaC 억제제로서의 벤조디아졸륨 화합물 Active KR102517273B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1619694.1 2016-11-22
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds
PCT/GB2017/053499 WO2018096325A1 (en) 2016-11-22 2017-11-22 Benzodiazolium compounds as enac inhibitors

Publications (2)

Publication Number Publication Date
KR20190084076A KR20190084076A (ko) 2019-07-15
KR102517273B1 true KR102517273B1 (ko) 2023-04-03

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016141A Active KR102517273B1 (ko) 2016-11-22 2017-11-22 ENaC 억제제로서의 벤조디아졸륨 화합물

Country Status (20)

Country Link
US (4) US10941149B2 (https=)
EP (1) EP3544981B1 (https=)
JP (1) JP6980014B2 (https=)
KR (1) KR102517273B1 (https=)
CN (1) CN110214141B (https=)
AU (1) AU2017364308B2 (https=)
CA (1) CA3043132A1 (https=)
DK (1) DK3544981T3 (https=)
EA (1) EA039607B1 (https=)
ES (1) ES2890226T3 (https=)
GB (1) GB201619694D0 (https=)
HU (1) HUE055692T2 (https=)
IL (1) IL266745B (https=)
MA (1) MA46878A (https=)
MX (1) MX389496B (https=)
PL (1) PL3544981T3 (https=)
PT (1) PT3544981T (https=)
TW (1) TWI756305B (https=)
WO (1) WO2018096325A1 (https=)
ZA (1) ZA201902710B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) * 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) * 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
PH12021553110A1 (en) 2019-06-12 2022-08-01 Tmem16A Ltd Compounds for treating respiratory disease
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
EP4259607A1 (en) 2020-12-11 2023-10-18 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
GB202406247D0 (en) 2024-05-03 2024-06-19 Enterprise Therapeutics Ltd Compounds and pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521325A (ja) 2003-10-28 2007-08-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド イオンチャネルのモジュレーターとして有用なベンズイミダゾール
WO2016113167A1 (en) 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7375107B2 (en) 2003-08-18 2008-05-20 Parion Sciences, Inc. Alaphatic pyrazinoylguanidine sodium channel blockers
JP2007502829A (ja) 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 環状ピラジノイルグアニジンナトリウムチャネルブロッカー
ES2432529T3 (es) 2003-08-18 2013-12-04 Parion Sciences, Inc. Bloqueadores del canal de sodio de pirazinoilguanidina rematada
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
ES2400287T3 (es) * 2005-03-14 2013-04-08 High Point Pharmaceuticals, Llc Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8288391B2 (en) 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
ES2485642T3 (es) 2008-02-26 2014-08-14 Parion Sciences, Inc. Bloqueantes poli-aromáticos de los canales de sodio
CA2723938A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases
JP2011522860A (ja) 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR102006612B1 (ko) 2011-11-02 2019-08-02 베링거 인겔하임 인터내셔날 게엠베하 헤테로사이클릭 화합물, 상기 화합물을 포함하는 약제, 이의 용도, 및 이의 제조 방법
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
HUE039734T2 (hu) 2012-05-29 2019-01-28 Parion Sciences Inc Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
US8841309B2 (en) 2012-09-24 2014-09-23 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
EP2991981B1 (en) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
AU2014284268A1 (en) 2013-07-02 2016-01-07 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
EP3019492B1 (en) 2013-07-08 2017-09-06 Boehringer Ingelheim International GmbH Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
JP6461134B2 (ja) 2013-07-15 2019-01-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ベンゾイミダゾリウム化合物
WO2015007516A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel 5-substituted benzimidazolium compounds
WO2015018754A1 (en) 2013-08-08 2015-02-12 Boehringer Ingelheim International Gmbh Novel pyrazine amide compounds
WO2016113169A1 (en) 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
JP6847838B2 (ja) 2015-01-12 2021-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 上皮ナトリウムチャネル阻害剤としての２−（ピラジン−２−イルカルボニルアミノメチル）ベンズイミダゾリウム化合物
US9932324B2 (en) 2015-01-12 2018-04-03 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
MX370598B (es) 2015-08-20 2019-12-18 Boehringer Ingelheim Int Fenoxiacetamidas apareadas novedosas.
EA201890532A1 (ru) 2015-08-20 2018-09-28 Бёрингер Ингельхайм Интернациональ Гмбх Новые аннелированные бензамиды
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521325A (ja) 2003-10-28 2007-08-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド イオンチャネルのモジュレーターとして有用なベンズイミダゾール
WO2016113167A1 (en) 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

Also Published As

Publication number Publication date
AU2017364308B2 (en) 2021-03-11
MX389496B (es) 2025-03-20
IL266745B (en) 2021-12-01
WO2018096325A1 (en) 2018-05-31
EP3544981A1 (en) 2019-10-02
KR20190084076A (ko) 2019-07-15
NZ753048A (en) 2024-09-27
EP3544981B1 (en) 2021-06-23
US20210147432A1 (en) 2021-05-20
ES2890226T3 (es) 2022-01-18
TWI756305B (zh) 2022-03-01
US12371436B2 (en) 2025-07-29
CA3043132A1 (en) 2018-05-31
CN110214141A (zh) 2019-09-06
ZA201902710B (en) 2021-10-27
HUE055692T2 (hu) 2021-12-28
PL3544981T3 (pl) 2021-12-20
US20190315757A1 (en) 2019-10-17
TW201833111A (zh) 2018-09-16
JP2019535747A (ja) 2019-12-12
GB201619694D0 (en) 2017-01-04
MX2019005934A (es) 2019-11-12
JP6980014B2 (ja) 2021-12-15
US11739094B2 (en) 2023-08-29
EA039607B1 (ru) 2022-02-16
US20250304590A1 (en) 2025-10-02
EA201991253A1 (ru) 2019-11-29
IL266745A (en) 2019-07-31
US10941149B2 (en) 2021-03-09
AU2017364308A1 (en) 2019-05-23
PT3544981T (pt) 2021-09-23
DK3544981T3 (da) 2021-09-20
MA46878A (fr) 2019-10-02
US20240067653A1 (en) 2024-02-29
BR112019009864A2 (pt) 2019-08-27
CN110214141B (zh) 2022-05-31

Similar Documents

Publication Publication Date Title
KR102517273B1 (ko) ENaC 억제제로서의 벤조디아졸륨 화합물
EP3794002B1 (en) Compounds
KR101152719B1 (ko) 피리미딘 유도체
ES2398428T3 (es) Derivados de triazol útiles para el tratamiento de enfermedades
KR101578587B1 (ko) ＥＮａＣ 차단제로서의 피라진 유도체
MX2015004327A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
EP3472154A1 (en) Compounds
EP3697788B1 (en) Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1h-1,3-benzodiazol-3-ium derivatives as enac inhibitors for treating respiratory diseases
HK40014276B (en) Benzodiazolium compounds as enac inhibitors
HK40014276A (en) Benzodiazolium compounds as enac inhibitors
BR112019009864B1 (pt) Compostos de benzodiazolínio, composição farmacêutica e produto compreendendo os referidos compostos, seus processos de fabricação e uso

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4